Click here to view the presentation slides from this CME-certified series held at select ASCO®* state affiliate meetings. (coming soon)
*ASCO® is a registered trademark of the American Society of Clinical Oncology. These programs are not ASCO® events.
The advent of targeted therapies significantly improved outcomes for patients with non-small cell lung cancer (NSCLC). However, those benefits are not uniform in all patients. There is a critical need to develop novel approaches that optimize patient outcomes. Immunotherapies have shown great promise in advanced NSCLC and could constitute a shift in clinical practice in the near future. Community oncologists must stay up to date with ongoing studies of immunotherapies and strategies to monitor response and immune-related adverse events in patients with advanced NSCLC.
Targeting the Immune System to Improve Patient Outcomes in Advanced NSCLC will provide guidance on the role of immunotherapy in patients with advanced NSCLC and explore molecular targets and mechanisms of action, clinical data for novel immunotherapies, strategies for monitoring and managing immune-related adverse events, and empowerment of patients to be active participants in treatment planning.
Welcome and Introductions
Role of Immunotherapy in NSCLC
Clinical Case-based Discussions
Case 1 – A patient with newly diagnosed PD-L1 positive metastatic NSCLC
Case 2 – A patient with NSCLC whose disease has progressed beyond frontline therapy with platinum-based chemotherapy
Role of Biomarkers in Patient Selection for Immunotherapies
Q&A Session, Closing Remarks
This program is intended for oncologists, pathologists, pulmonologists, thoracic surgeons, intervention radiologists, nurses, and other health care professionals involved in the care of patients with NSCLC.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Evaluate mechanisms of action of immunotherapies in advanced NSCLC
- Assess emerging data for immune checkpoint inhibitors in advanced NSCLC
- Discuss the role of biomarkers in patient selection for immunotherapies
- Educate patients with NSCLC about promising immunotherapeutic agents and clinical trial opportunities
Suresh S. Ramalingam, MD
Professor of Hematology and Medical Oncology
Director, Division of Medical Oncology
Winship Cancer Institute
Suresh S. Ramalingam, MD is Professor of Hematology and Medical Oncology and Director of the Division of Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine, in Atlanta, GA.
Dr. Ramalingam received his medical degree at Kilpauk Medical College in Madras, India. He completed his residency in internal medicine at Wayne State University in Detroit, MI, where he also served as Chief Medical Resident. He then completed a fellowship in hematology and medical oncology at the University of Pittsburgh Medical Center in Pittsburgh, PA.
Dr. Ramalingam serves as the Chair of the Eastern Cooperative Oncology Group Thoracic Malignancies Committee. He also serves on the Editorial Board of leading cancer journals, such as the Journal of Clinical Oncology, Cancer, Clinical Lung Cancer, and Cancer Chemotherapy and Pharmacology. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology at Emory University, and the Distinguished Cancer Scholar Award from the Georgia Cancer Coalition. In addition, he received the American Society of Clinical Oncology Career Development Award (2006–2009) and the National Cancer Institute Clinical Investigators Team Leadership Award (2010-2012). Dr. Ramalingam serves on several international, national, and institutional committees.
Dr. Ramalingam’s research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. He has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. His research has been published in leading journals such as the Journal of Clinical Oncology, Lancet Oncology, Journal of the National Cancer Institute, and Cancer.
John Powderly II, MD, CPI
President, Carolina BioOncology Institute PLLC
Adjunct Clinical Assistant Professor of Medicine
University of North Carolina School of Medicine
Duke University School of Medicine
John Powderly II, MD, CPI grew up in Fairfax, VA and graduated from George Mason University in 1991 with a bachelor of science in biology. He then attended Georgetown Medical School and was awarded the Lawrence Dean Scholarship. He spent his senior year at the National Cancer Institute (NCI) as an intern on the Immunotherapy Service. He then attended the University of Texas at Houston Health Science Center for a combined medicine/pediatrics residency from 1995-1999. In 1999-2000 he was appointed faculty at MD Anderson Cancer Center and performed additional melanoma immunotherapy research. His oncology fellowship at the University of North Carolina (UNC), Chapel Hill, focused on dendritic cell immunotherapy.
Becoming triple board-certified in internal medicine, pediatrics, and medical oncology, he relocated to Charlotte, NC and built a community-based oncology research program. In 2003, he became Chairman of the Cancer Research Committee at Presbyterian Cancer Center. He also became Section Chief of the Hematology/Oncology Division on the Medical Executive Committee at Carolinas Medical Center (CMC) Mercy Hospital, and served on the Executive Cancer Committee of CMC Charlotte.
In 2005, Dr. Powderly founded Carolina BioOncology Institute (CBOI), a cancer therapy and research center that focuses on early phase immunotherapy trials. This community-based clinic in Huntersville, NC is the only independent dedicated phase I cancer center on the East Coast. CBOI has opened more than 50 early phase clinical trials and treated more than 3,000 cancer patients, and serves as a regional referral hub for phase I access in the community setting.
Dr. Powderly’s research publications on early phase immunotherapy research have appeared in more than 40 publications, including the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Immunotherapy, Nature, Clinical Cancer Research, Clinical Chemistry, and Investigational New Drugs. Some of his articles and presentations have been recognized as “top 50 most cited articles by JCO” and “top 10 most downloaded ASCO Video Presentations.” He has also served as a reviewer for multiple cancer journals and as an NIH grant reviewer, and is an Adjunct Clinical Assistant Professor of Medicine at both Duke and UNC.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided after submission of a completed evaluation form.
There is no fee associated with this program.
Event staff will be glad to assist you with any specials needs. Please email email@example.com at least 5 days prior to the program.
Jointly provided by the Potomac Center for Medical Education and Rockpointe Oncology
Supported by an independent educational grant from Genentech and Merck.
By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.